Cargando…

The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease

Alzheimer’s disease (AD) is a chronic neurodegenerative disease, which is associated with learning and memory impairment in the elderly. Recent studies have found that treating AD in the way of chromatin remodeling via histone acetylation is a promising therapeutic regimen. In a number of recent stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Shuang-shuang, Zhang, Rui, Wang, Gang, Zhang, Yong-fang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504819/ https://www.ncbi.nlm.nih.gov/pubmed/28702178 http://dx.doi.org/10.1186/s40035-017-0089-1

Ejemplares similares

HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases
por: Yoon, Somy, et al.
Publicado: (2019)

Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia
por: Toutah, Krimo, et al.
Publicado: (2021)

Potential Therapeutic Role of HDAC Inhibitors in FUS-ALS
por: Tejido, Clara, et al.
Publicado: (2021)

Development of a potential PET probe for HDAC6 imaging in Alzheimer's disease
por: Bai, Ping, et al.
Publicado: (2022)

Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors
por: Galán, María, et al.
Publicado: (2016)

A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer’s disease and tauopathy in mice
por: Onishi, Tomohiro, et al.
Publicado: (2021)

HDAC inhibitors in kidney development and disease
por: Brilli, Lauren L., et al.
Publicado: (2012)

The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
por: Cosenza, Maria, et al.
Publicado: (2018)

HDAC4 Inhibitors as Antivascular Senescence Therapeutics
por: Huang, Chuoji, et al.
Publicado: (2022)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
por: Thomas, Elizabeth A.
Publicado: (2014)

HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
por: Yoon, Somy, et al.
Publicado: (2016)

Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment
por: Sun, Yichen, et al.
Publicado: (2022)

Therapeutic Potential of Direct Clearance of the Amyloid-β in Alzheimer’s Disease
por: Kim, Dong Eun, et al.
Publicado: (2020)

HDAC inhibitors and their potential applications to glioblastoma therapy
por: Adamopoulou, Eleni, et al.
Publicado: (2013)

Valeric Acid Suppresses Liver Cancer Development by Acting as a Novel HDAC Inhibitor
por: Han, Rui, et al.
Publicado: (2020)

Decreased levels of circulating trimethylamine N-oxide alleviate cognitive and pathological deterioration in transgenic mice: a potential therapeutic approach for Alzheimer’s disease
por: Gao, Qiang, et al.
Publicado: (2019)

A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors
por: Fontana, Anna, et al.
Publicado: (2022)

New Insight in HDACs: Potential Therapeutic Targets for the Treatment of Atherosclerosis
por: Luan, Yi, et al.
Publicado: (2022)

Potential contributions of trace amines in Alzheimer’s disease and therapeutic prospects
por: Dhakal, Sudip, et al.
Publicado: (2020)

Targeting HDACs: A Promising Therapy for Alzheimer's Disease
por: Xu, Ke, et al.
Publicado: (2011)

HDAC4 in ischemic stroke: mechanisms and therapeutic potential
por: Kong, Qingsheng, et al.
Publicado: (2018)

Therapeutic potential of HDAC6 in amyotrophic lateral sclerosis
por: Guo, Wenting, et al.
Publicado: (2017)

Host histone acetylation unlocks HDAC inhibitor potential
por: Terranova-Barberio, Manuela, et al.
Publicado: (2017)

The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
por: Vaca, Hugo Rolando, et al.
Publicado: (2021)

Aaptamine – a dual acetyl – and butyrylcholinesterase inhibitor as potential anti-Alzheimer’s disease agent
por: Miao, Shuang, et al.
Publicado: (2022)

Investigating the Synergistic Potential of Low-Dose HDAC3 Inhibition and Radiotherapy in Alzheimer’s Disease Models
por: Ricciardi, Natalie R., et al.
Publicado: (2023)

Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
por: King, Jacob, et al.
Publicado: (2021)

Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction
por: Sharma, Chiranjeev, et al.
Publicado: (2019)

Discovery of New Uracil and Thiouracil Derivatives as Potential HDAC Inhibitors
por: Elbatrawy, Omnia R., et al.
Publicado: (2023)

Role of Monoamine Oxidase Activity in Alzheimer’s Disease: An Insight into the Therapeutic Potential of Inhibitors
por: Behl, Tapan, et al.
Publicado: (2021)

Therapeutic Prospect of New Probiotics in Neurodegenerative Diseases
por: Bi, Mingxia, et al.
Publicado: (2023)

Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer
por: Guerra, Fabiana Sélos, et al.
Publicado: (2021)

Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors
por: Kutil, Zsófia, et al.
Publicado: (2019)

HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain
por: Denk, Franziska, et al.
Publicado: (2013)

Ring size changes in the development of class I HDAC inhibitors
por: Cho, Er-Chieh, et al.
Publicado: (2021)

GW5074 Increases Microglial Phagocytic Activities: Potential Therapeutic Direction for Alzheimer’s Disease
por: Connor, Sarah M., et al.
Publicado: (2022)

Amyloidosis in Alzheimer’s Disease: Pathogeny, Etiology, and Related Therapeutic Directions
por: Ma, Chen, et al.
Publicado: (2022)

Potential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors
por: Wang, Yuqian, et al.
Publicado: (2023)

Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines
por: Pinkerneil, Maria, et al.
Publicado: (2016)

Exploration of thiaheterocyclic hHDAC6 inhibitors as potential antiplasmodial agents
por: Vreese, Rob De, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_eck4cin1g77tn30qnudekk8i8o